Comparison of the prediction performance of different warfarin dosing algorithms based on Chinese patients [0.03%]
基于中国患者的华法林剂量预测算法的比较研究
Cheng Xie,Ling Xue,Yuzhen Zhang et al.
Cheng Xie et al.
Aim: To compare the prediction performance of different warfarin dosing algorithms based on Chinese patients. Materials & methods: A total of 18 algorithms were tested in 325 patients. The predictive efficacy of selected algorithms was eval...
Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update [0.03%]
类风湿性关节炎中甲氨蝶呤反应的药物基因组学研究进展
Stephanie F Ling,James Bluett
Stephanie F Ling
Circulating tumor DNA (ctDNA) in precision oncology of ovarian cancer [0.03%]
循环肿瘤DNA（ctDNA）在卵巢癌精准治疗中的作用
Jaana Oikkonen,Sampsa Hautaniemi
Jaana Oikkonen
Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment [0.03%]
循环肿瘤DNA和EGFR突变型肺癌治疗的未来方向
Marzia Del Re,Alfredo Addeo,Antonio Passaro et al.
Marzia Del Re et al.
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma [0.03%]
与黑色素瘤患者威罗菲尼相关毒性的药效遗传变异的影响
Andrew Kl Goey,Mirjam de With,Bram C Agema et al.
Andrew Kl Goey et al.
Aim: The pharmacokinetics and pharmacodynamics of vemurafenib are characterized by a wide interpatient variability. Since multiple polymorphic enzymes and drug transporters are involved in vemurafenib pharmacokinetics, we studied associatio...
Pharmacogenomics in the clinic: genetic polymorphism contributing to venlafaxine-associated heart failure [0.03%]
门诊药物基因组学：与文拉法辛相关的心力衰竭的遗传多态性
Harleen Singh,Barent DuBois,Zain Al-Jammali et al.
Harleen Singh et al.
CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer [0.03%]
在中国激素受体阳性乳腺癌患者中，基于CYP2D6*10药物基因组学指导的SERM治疗可能是一种具有成本效益的策略
Xiaoxia Wei,Jiaqin Cai,Jie Zhuang et al.
Xiaoxia Wei et al.
Aim: To assess the cost-effectiveness of CYP2D6*10 genetic testing for the management of Chinese women with hormone receptor-positive (HR+) breast cancer treated with selective estrogen receptor modulator. Methods: A Markov model was develo...
Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation [0.03%]
器官移植受者基因分型临床应用的相关研究及利益关系人的视角观点综述
Kimberly M Deininger,Jacinda N Tran,Shirley M Tsunoda et al.
Kimberly M Deininger et al.
Aims: To assess stakeholder perspectives regarding the clinical utility of pharmacogenomic (PGx) testing following kidney, liver, and heart transplantation. Methods: We conducted individual semi-structured interviews and focus groups with k...
Georgia Ragia,Vangelis G Manolopoulos
Georgia Ragia
The effects of rosiglitazone on the neonatal rat cardiomyocyte transcriptome: a temporal analysis [0.03%]
罗格列酮对新生大鼠心肌细胞转录的影响：时间进程分析
Willian Abraham da Silveira,Esteban Vazquez-Hidalgo,Elesha Bartolotta et al.
Willian Abraham da Silveira et al.
Aim: The objective was to determine via high-throughput RNA sequencing the temporal effects of rosiglitazone (Avandia®) on the neonatal rat ventricular myocyte transcriptome. Materials & methods: Neonatal rat ventricular myocytes (NRVMs) w...